It is important to monitor ␤-lactam antimicrobial nonsusceptibility trends for Streptococcus pneumoniae to inform empirical treatment guidelines. In this study, we describe penicillin and ceftriaxone susceptibility trends using national laboratorybased pneumococcal surveillance data from 2003 to 2010. A sentinel enhanced-site patient subset (2009 to 2010) contributed to the risk factor and mortality analyses. We included 9,218 invasive pneumococcal disease (IPD) cases for trend analyses and 2,854 IPD cases for risk factor and mortality analyses. Overall, we detected no significant changes in penicillin (patients <5 years of age, P ‫؍‬ 0.50; patients >5 years of age, P ‫؍‬ 0.05) or ceftriaxone nonsusceptibility rates (patients <5 years of age, P ‫؍‬ 0.21; patients >5 years of age, P ‫؍‬ 0.60). Factors associated with ceftriaxone nonsusceptibility on multivariate analysis were an age of <5 years (<1 year of age: adjusted odds ratio [aOR], 2.87; 95% confidence interval [CI], 1.70 to 4.86; 1 to 4 years of age: aOR, 2.58; 95% CI, 1.53 to 4.35, versus 25 to 44 years of age), province (Gauteng [aOR, 2.46; 95% CI, 1.26 to 4.84], and Northern Cape [aOR, 4.52; 95% CI, 1.95 to 10.52] versus KwaZulu-Natal), ␤-lactam use within 24 h preceding admission (aOR, 2.52; 95% CI,  1.41 to 4.53), and 13-valent vaccine serotypes (aOR, 51.64; 95% CI, 7.18 to 371.71) . Among patients >5 years of age with meningitis who were treated according to current guidelines, HIV-infected patients (aOR, 2.94; 95% CI, 1.32 to 6.54) and patients infected with ceftriaxone-nonsusceptible isolates (aOR, 3.17; 95% CI, 1.27 to 7.89) had increased mortality rates. Among children <5 years of age with meningitis, mortality was increased in HIV-infected patients (aOR, 3.04; 95% CI, 1.40 to 6.56) but not in those with ceftriaxone-nonsusceptible isolates. Penicillin and ceftriaxone nonsusceptibility remained stable over the study period. Ceftriaxone nonsusceptibility was associated with increased mortality among patients >5 years of age with meningitis. The introduction of a pneumococcal conjugate vaccine may reduce ceftriaxone-nonsusceptible meningitis.
S treptococcus pneumoniae is a leading global cause of invasive bacterial infections in children, with the highest incidence of disease in Africa. In 2000, it was estimated that approximately 14.5 million episodes of severe disease and 826,000 deaths occurred in children age 1 to 59 months worldwide (1) . Following the introduction of the pneumococcal conjugate vaccine (PCV) in routine immunization programs, decreases in pneumonia hospitalization rates in children (2, 3) and overall rates of pneumococcal meningitis in adults and children (4) have been noted.
During the 1990s in South Africa, penicillin nonsusceptibility among pneumococcal isolates causing invasive pneumococcal disease (IPD) in all age groups increased from 10% (1991 to 1994 period) to 18% (1995 to 1998 period). The proportion of high-level penicillin resistance did not change significantly over this period, remaining at 8 to 10% of all isolates (5) . More recent national surveillance data showed a significant increase in penicillin nonsusceptibility, from 23% (2003) to 38% (2008) (P Ͻ 0.001), but not in ceftriaxone nonsusceptibility, over the same period (6) .
In the prevaccine era in the United States, penicillin nonsusceptibility in pneumococci causing IPD increased over 10 years to Ͼ20% by 1998 (7) . Similarly, ceftriaxone resistance increased from 5.1% in 1995 (8) to 24 .7% in 2000 (9) , but this surveillance included invasive as well as noninvasive specimens. A review of 12 studies among children with IPD from Europe reported an overall pneumococcal resistance rate to third-generation cephalosporins of 9% (10) .
Mortality due to untreated meningitis is high and has been described as approaching 100% (11) . With treatment, mortality depends on age, underlying conditions or immunosuppression, and illness severity (12, 13) . In some studies, increased mortality was reported when patients with penicillin-nonsusceptible strains causing meningitis were treated with penicillin (14) , and increased failure was reported when extended-spectrum cephalosporins were used to treat patients with cephalosporin-nonsusceptible meningitis (15) . Similar outcomes have occurred between patients infected by cephalosporin-susceptible and -nonsuscep-tible strains when patients receive extended-spectrum cephalosporins plus vancomycin (16) .
The aims of our study were to describe trends in South Africa in pneumococcal ceftriaxone nonsusceptibility, using broth microdilution over an 8-year period, to determine the risk factors for ceftriaxone nonsusceptibility, and to determine if ceftriaxone nonsusceptibility is associated with an increased risk of mortality in meningitis patients Ͻ5 years and Ն5 years of age.
MATERIALS AND METHODS
Study design and definitions. We conducted a secondary analysis using Group for Enteric, Respiratory, and Meningeal disease Surveillance in South Africa (GERMS-SA) national laboratory-based surveillance program data collected from 1 January 2003 through 31 December 2010. Laboratories submitted reports of laboratory-confirmed IPD along with the respective isolates to the National Institute for Communicable Diseases in Johannesburg, South Africa. Basic demographic data were collected for all cases, and in 24 enhanced surveillance sites, demographic and clinical data were obtained by surveillance officers through patient interviews and/or medical records.
An IPD case was defined as S. pneumoniae isolated from a normally sterile site, such as cerebrospinal fluid (CSF), blood, or pleural or joint fluid. Pneumococcal meningitis was defined as S. pneumoniae identified from CSF or a clinical diagnosis of meningitis made by the attending clinician along with a positive blood culture for S. pneumoniae. Bacteremic pneumonia was defined as a clinical diagnosis of pneumonia noted in clinical records, along with pneumococcus isolated from blood culture. Bacteremia without focus had no localizing clinical diagnosis noted in the clinical records, along with S. pneumoniae isolated from blood culture.
Underlying medical conditions were categorized as chronic conditions, central nervous system conditions, immunosuppressive conditions or treatment, metabolic diseases, alcohol dependency and smoking, chromosomal disorders, protein-energy malnutrition, and tuberculosis. The degree of immunosuppression was based on World Health Organization categories using the most recent CD4 ϩ lymphocyte count or CD4 ϩ percentage (%CD4 ϩ ) of the total lymphocyte cell count. Advanced/severe immunosuppression was defined as a CD4 ϩ count of Յ350 cells per mm 3 in individuals Ͼ5 years of age, a %CD4 ϩ of Ͻ30% in children Ͻ11 months of age, a %CD4 ϩ of Ͻ25% in children 12 to 35 months of age, and a %CD4 ϩ of Ͻ20% in children 36 to 59 months of age (17) . The severity of illness was determined using the length of hospital stay, the Pitt bacteremia score (severe disease score, Ն4) (18) , and the Glasgow coma scale score. Length of hospital stay, regardless of final outcome, was divided into 3 categories: patients who died/were discharged before 15 days, patients who were discharged between 15 and 30 days, and patients whose outcome was after 1 month during hospital stay.
To determine whether patients with meningitis caused by ceftriaxone-nonsusceptible isolates were more likely to die, we examined inhospital mortality, regardless of the length of hospital stay, in meningitis patients who were treated according to current local meningitis guidelines for ceftriaxone-susceptible disease, namely, third-or fourth-generation cephalosporin, imipenem, or meropenem (19) . Patients who received a cephalosporin plus vancomycin were excluded, as this was not recommended in our guidelines at the time. Our main objective was to assess the effect of resistance on mortality using our current guidelines in order to address possible changes to those guidelines. An adequate dose of cefotaxime or ceftriaxone was defined as 50 mg/kg of body weight/dose for children or 2 g/dose for adults every 6 or 12 h, respectively (19, 20) .
Laboratory methods. S. pneumoniae identification was based on standardized methodologies (21) . Pneumococcal isolates were serotyped by Quellung reaction using serum samples from Statens Serum Institute (SSI), Copenhagen, Denmark. Ten-valent pneumococcal conjugate vaccine (PCV-10) serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, and additional 13-valent pneumococcal conjugate vaccine (PCV-13) serotypes, 3, 6A, and 19A.
The 2010 Clinical and Laboratory Standards Institute (CLSI) MIC meningitis breakpoints were used to analyze resistance to penicillin (susceptible, Յ0.06 g/ml; resistant, Ն0.12 g/ml) and ceftriaxone (susceptible, Յ0.5 g/ml; intermediate, 1 g/ml; resistant, Ն2 g/ml) (22) , with intermediate and resistant isolates categorized as nonsusceptible to penicillin and ceftriaxone.
In 2009, MIC testing was changed to the CLSI-recommended broth microdilution method using commercially prepared Trek panels (Trek Diagnostics Inc., Westlake, OH, USA) containing Mueller-Hinton broth supplemented with 5% lysed horse blood (23) . To ensure standard MIC methodology for the years prior to 2009, we used simple random sampling to sample approximately 500 isolates from 2003 to 2008 for retesting using the broth microdilution method. As some of the randomly chosen isolates were nonviable on subculture, the exact numbers tested per year Statistical analysis. A chi-square test for trend assessed penicillin and ceftriaxone resistance prevalences from 2003 to 2010 among viable S. pneumoniae isolates; the analyses were also stratified by age groups (Ͻ5 and Ն5 years). Individuals with unknown ages were excluded from the analyses.
Univariate and multivariate analyses were performed using Stata version 12 (StataCorp Limited). To determine the risk factors that predict ceftriaxone nonsusceptibility and the factors associated with mortality, we included all cases with viable isolates from enhanced sites for 2009 and 2010 in two multivariate models. All covariates with a P value of Յ0.10 on univariate analysis were included in the logistic regression model for multivariate analysis, and all nonsignificant factors (assessed at P Ն 0.05) were dropped employing stepwise backward selection. In the multivariate model, patients with missing data were dropped from the model. To explore the possible bias introduced by restricting the analysis to patients at the enhanced surveillance sites, we compared the characteristics among patients presenting to enhanced and nonenhanced sites.
Ethics. Ethics approval was obtained for GERMS-SA surveillance (M081117) and secondary data analysis (M110634) from the Human Research Ethics Committee (Medical), University of the Witwatersrand, Johannesburg, South Africa.
RESULTS
In total, 36,679 IPD laboratory-confirmed cases were identified through the surveillance program from 2003 through 2010. We included a sample of 8,887 cases with isolates tested for penicillin and ceftriaxone susceptibility using broth microdilution for trend analyses ( Fig. 1 ) and 2,854 individuals from 2009 and 2010, with complete clinical and resistance data, in the risk factor and mortality analyses ( Fig. 1 
Trends in penicillin and ceftriaxone nonsusceptibility from 2003 through 2010 for children <5 years of age and individuals
>5 years of age. In individuals whose ages were known (8,887/ 9,216 [96%]), the overall prevalence of penicillin nonsusceptibility was 43% (3,809/8,887), ranging from 43% (182/425) in 2003 to 42% (1,164/2,768) in 2010. Children Ͻ5 years of age had a higher prevalence of penicillin nonsusceptibility (1,625/2,631 [62%]) than individuals Ն5 years of age (2,184/6,256 [35%]) (P Ͻ 0.001) ( Fig. 2A) . Similarly, the overall prevalence of ceftriaxone nonsusceptibility was 8% (706/8,887), ranging from 7% (32/425) in 2003 to 8% (214/2,768) in 2010. Children Ͻ5 years of age had a higher prevalence of ceftriaxone nonsusceptibility (338/2,631 [13%]) than did older individuals (368/6,256 [6%]) (P Ͻ 0.001) ( Fig. 2B ). Over 80% of all ceftriaxone-nonsusceptible isolates were intermediately resistant (over the study period, high-level resistance ranged from 1.7% to 3.4% of nonsusceptible isolates in children Ͻ5 years old and 0.3% to 1.8% of nonsusceptible isolates in patients Ն5 years old).
From 2003 through 2010, there was no significant change in penicillin or ceftriaxone nonsusceptibility in children Ͻ5 years of age (P ϭ 0.50 and 0.21, respectively), while in individuals Ն5 years of age, the increase was borderline for penicillin nonsusceptibility (P ϭ 0.05), with no significant change in ceftriaxone nonsusceptibility (P ϭ 0.60) ( Fig. 2 ).
Risk factors for ceftriaxone nonsusceptibility in patients
with viable isolates from GERMS-SA enhanced sites for all age groups from 2009 to 2010. Using multivariate analysis, patients with ceftriaxone-nonsusceptible isolates were significantly more likely to be Ͻ5 years of age (Ͻ1 year: adjusted odds ratio [aOR], 2.87; 95% CI, 1.70 to 4.86 and 1 to 4 years: aOR, 2.58; 95% CI, 1.53 to 4.35) than 25 to 44 years of age, more likely to be from Gauteng Province (aOR, 2.46; 95% CI, 1.26 to 4.84) and Northern Cape (aOR, 4.52; 95% CI, 1.95 to 10.52) than from KwaZulu-Natal, more likely to have used any ␤-lactam antibiotics in the last 24 h (aOR, 2.52; 95% CI, 1.41 to 4.53), and more likely to have disease due to a serotype in PCV-13 (aOR, 51.64; 95% CI, 7.18 to 371.71) ( Table 1) . A separate multivariate analysis using PCV-10 instead of PCV-13 serotypes was also explored, and the results were similar (aOR, 12.66; 95% CI, 6.91 to 23.20 for PCV-10 serotypes).
Risk factors for mortality among individuals with meningitis treated according to guidelines for ceftriaxone-susceptible disease for all age groups from 2009 to 2010. In children Ͻ5 years old with meningitis (Table 2) , mortality was highest in children Ͻ1 year of age (aOR, 2.72; 95% CI, 1.20 to 6.12) and who were HIV infected (aOR, 3.04; 95% CI, 1.40 to 6.56). Ceftriaxone non-susceptibility was not associated with increased mortality (aOR, 0.69; 95% CI, 0.23 to 2.10). Children generally died within 2 weeks of admission (15 to 30 days: aOR, 0.07; 95% CI, 0.02 to 0.31; Ͼ30 days: aOR, 0.13; 95% CI, 0.03 to 0.64), and severely ill children with a Pitt bacteremia score of Ն4 (aOR, 10.89; 95% CI, 3.90 to 30.36) were more likely to die.
For individuals Ն5 years of age (Table 3) , mortality was higher in the older age groups than in children 5 to 14 years old (15 to 44 years: aOR, 5.96; 95% CI, 2.59 to 13.72; 45 to 64 years old: aOR, 9.37; 95% CI, 3.67 to 23.90), HIV-infected patients (aOR, 2.94; 95% CI, 1.32 to 6.54), and patients with ceftriaxone-nonsusceptible isolates (aOR, 3.17; 95% CI, 1.27 to 7.89). Most patient deaths occurred within 2 weeks of hospital admission (15 to 30 days: aOR, 0.23; 95% CI, 0.13 to 0.41; Ͼ30 days: aOR, 0.14; 95% CI, 0.03 to 0.56). Patients with severe disease (Pitt bacteremia score of Ն 4) (aOR, 7.91; 95% CI, 3.73 to 16.77) were also more likely to die. The median length of hospital stay among meningitis patients who died was 5 days (range, 0 to 84 days), while for patients who lived, it was 15 days (range, 0 to 108 days) (P Ͻ 0.001) ( Fig. 3 ). Patients without meningitis had a median length of stay similar to that of meningitis patients, both for patients who died (4 days [range, 0 to 82 days]) and for patients who recovered (11 days [range, 0 to 216 days]).
A total of 1,123 individuals with available data on age were diagnosed with meningitis, and of these, 1,077 had complete treatment records. Among individuals with known prescribed treatment, 87% (938/1,077) (85% [263/308] were children Ͻ5 years of age, and 88% [675/769] were individuals Ն5 years of age) were given antibiotics according to the guidelines for ceftriaxone-susceptible pneumococcal meningitis. This group excluded 54 (4%) patients (22 [6%] children and 32 [4%] older individuals) who received both vancomycin and ceftriaxone. Only 8% (88/1077) of the patients received carbapenems (33 children and 55 adults). When we reviewed patients who received third-generation cephalosporins, the dosages of treatment for meningitis were generally adequate for both groups (82% [262/320] of children Ͻ5 years of age and 77% [556/719] of individuals Ն5 years of age) (P ϭ 0.11).
DISCUSSION
Penicillin and ceftriaxone nonsusceptibility was highest in young children but did not significantly increase in any age group over the surveillance period. The risk factors identified for ceftriaxone nonsusceptibility (young age, province, antibiotic use, and vaccine serotype) are similar to those previously described in the literature (24) . We demonstrated that pneumococcal ceftriaxone nonsusceptibility was associated with increased mortality in individuals Ն5 years of age but not in young children Ͻ5 years of age.
The high mortality rate from pneumococcal meningitis determined in our study is in line with what has been shown in other studies in countries with emerging resistance (14, 16) . We found a significant increase in mortality in individuals 5 to 64 years of age with ceftriaxone-nonsusceptible meningitis who were treated with a third-generation cephalosporin. The number of individuals (n ϭ 14) in the Ն65-year-age group was too small to show a significant increase in mortality in this subgroup (aOR, 8.60; 95% CI, 0.90 to 81.72). U.S. guidelines recommend a third-generation cephalosporin plus vancomycin as an empirical therapy due to its high levels of ␤-lactam resistance (25) . Vancomycin requires slow infusion over 60 to 120 min to avoid hypersensitivity reactions, as well as maintenance of trough serum concentrations (15 to 20 mg/liter) to improve drug penetration, increase the likelihood of obtaining optimal target serum concentrations, and improve clinical outcomes (26) . There is conflicting evidence from the United States regarding whether outcomes are worse among patients with cephalosporin-nonsusceptible pneumococci, as most patients receive concomitant treatment with vancomycin (16) . A previous South African study in children Ͻ15 years of age showed no association between penicillin nonsusceptibility and an increased risk of mortality from pneumococcal meningitis or other IPD, as most children received third-generation cephalosporin therapy for meningitis (13) . However, an earlier study from South Africa (27) and a study from Malawi did show increased mortality in children with penicillin-or chloramphenicol-nonsusceptible meningitis when they were treated with penicillin (28) . Although we did not find any significant difference in our study regarding the prescription of antibiotics according to the guidelines between children Ͻ5 years and individuals Ն5 years of age (P ϭ 0.11), we hypothesized that the more appropriate dosing of antibiotics for children (i.e., based on weight) and the likely more regular dosing in children resulted in more adequate levels of cephalosporins in children. ␤-lactam effectiveness is dependent on the time that antibiotic levels remain above the target MIC during any one dosing interval. With missed doses, antibiotic levels fall below the target MIC and are less bactericidal (29) . Congruent with our results, children have been reported in many studies to have higher rates of penicillin and ceftriaxone nonsusceptibility than adults (30) . The selective pressure of anti-biotics on pneumococci (30, 31) most likely explains our finding of higher ceftriaxone nonsusceptibility in children Ͻ5 years of age and patients reporting ␤-lactam antibiotic use in the last 24 h. We also identified variations in nonsusceptibility by province that may reflect differences in antibiotic use and availability and access to health care. These differences may apply to other countries where health care practices differ by region.
Previous analyses of penicillin and ceftriaxone from our surveillance system, using an agar dilution MIC methodology for isolates determined to be nonsusceptible by an oxacillin screening test, showed a significant increase in penicillin nonsusceptibility from 2003 to 2008 (23% to 38%) and low ceftriaxone nonsusceptibility (Ͻ1%) (6) . Our analysis, including only patients with isolates randomly selected for testing by broth microdilution methodology, showed a higher overall rate of penicillin and ceftriaxone nonsusceptibility (43% and 8%, respectively) for the study period, highlighting how this method increased the detection of penicillin-and ceftriaxone-resistant S. pneumoniae isolates. In addition, no increases in penicillin and ceftriaxone nonsusceptibility prevalences were observed during the study period, ranging from 42% to 43% and 7% to 8%, respectively, for all age groups. On further review, the reason for missing resistance was not the oxacillin screening disk diffusion test, which in our hands had a high sensitivity (99%) for detecting resistance compared with the broth microdilution MIC testing for penicillin; in contrast, the agar dilution MIC had a low sensitivity (74%) (data not shown). Discrepancies have been shown in reported cases of nonsusceptibility in a comparison of agar dilution and broth microdilution MIC methods, with agar dilution underreporting ceftriaxone resistance by 14% in one study (32) . Another study demonstrated good agreement with both methods, but ceftriaxone was not assessed (33) . Minor errors for penicillin and ceftriaxone MICs have been observed for commercial broth microdilution panels for pneumococci, such as those used in our study, by other investigators (34, 35) ; specifically, Trek panels appear to overreport resistance (32) .
In our study, this may have resulted in no misidentifications of resistant isolates as susceptible, but some susceptible isolates may have been misclassified as resistant.
Other antibiotics, including macrolides and fluoroquinolones, which are included in resistance monitoring in our surveillance system, showed no changes in reported resistance levels with the transition from agar dilution to broth microdilution MIC testing (data not shown). PCV-7 was introduced into the South African routine immunization program on 1 April 2009 and was replaced by PCV-13 in June 2011. By the end of 2010, the surveillance data from South Africa already showed a decrease in disease incidence in children Ͻ1 year of age compared to that in 2009 (73/100,000 in 2009 to 43/100,000 in 2010), while penicillin and ceftriaxone nonsusceptibility did not decline over this time period (36) . As resistance is closely linked to pneumococcal serotype, with time, a reduction in vaccine-type disease and nonsusceptible strains is expected (9, 37) . With the introduction and continued use of PCV, it is expected that drug-resistant isolates will decrease to levels below the threshold for which vancomycin is recommended to be added as part of first-line empirical treatment for bacterial meningitis (38) . Vancomycin is difficult to use in facilities that do not have resources for monitoring drug administration. This has implications for meningitis treatment at low-level facilities, especially in developing countries. The reduction in resistance is additional motivation for developing countries with poor surveillance and laboratory facilities to consider the introduction of this vaccine, as resistance in these countries may go unmonitored.
As with most surveillance studies, this study had limitations. Only patients who had samples taken were included, and they may not represent the general population. The final risk factor analysis included only cases from enhanced sites. Cases from enhanced sites with viable isolates involved patients that were younger than those from nonenhanced sites, were more likely to be diagnosed with positive blood cultures, and were more common in certain provinces. While these differences may have biased overall nonsusceptibility rates, they are unlikely to have influenced the factors that we found to be associated with nonsusceptibility. Prior to 2010, verbal reports were accepted as documentation of vaccination history and may have led to misclassifications. The impact of vaccination on serotypes and resistance therefore could not be fully evaluated. The accuracy and completeness of vaccination his- 0  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28 tory was improved in 2010 due to the addition of a nested casecontrol study at the enhanced surveillance sites, and ongoing surveillance will monitor the effects of PCV use on ceftriaxone nonsusceptibility among pneumococcal isolates in South Africa. The reasons for early and late mortality tend to differ, with inappropriate empirical treatment contributing to early mortality and comorbidities playing a bigger role in late mortality. In our analysis, only early death was fully explored. We were unable to accurately verify the level and number of doses given to individual patients and therefore could not include this variable in the mortality analysis. It is important to closely monitor S. pneumoniae resistance patterns in different countries to ensure that empirical treatment guidelines for community-acquired pneumonia and meningitis are appropriate for the local setting. The addition of vancomycin to empirical therapy regimens increases treatment complexity and costs compared to those of third-generation cephalosporin-only treatment. In addition, patients who need vancomycin ideally need to be treated immediately, before antimicrobial susceptibility testing results. Clinicians should consider the addition of vancomycin in high-risk groups when clinically indicated. Despite the high prevalence (8%) of ceftriaxone-nonsusceptible S. pneumoniae isolates, the majority (Ͼ80%) of these isolates were intermediately resistant and would still likely respond to adequate high-dose ceftriaxone. If ceftriaxone is used, it is important that no doses are missed and high drug levels are maintained. In developing countries with limited abilities to monitor resistance, the introduction of PCV will significantly impact resistance rates and may avoid the need to add vancomycin to current meningitis treatment regimens.
